# Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

> **NCT04161391** · PHASE1,PHASE2 · TERMINATED · sponsor: **Turning Point Therapeutics, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Medullary Thyroid Cancer
- RET Gene Mutation
- Metastatic Solid Tumor
- Advanced Solid Tumor

## Interventions

- **DRUG:** TPX-0046

## Key facts

- **NCT ID:** NCT04161391
- **Lead sponsor:** Turning Point Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-06
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Adverse change in the risk/benefit.
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161391, "Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04161391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*